Fig. 6: Gfi1 expression in T cells is required for anti-CTLA-4 efficacy.

WT and Gfi1^cKO mice inoculated with MB49 cells were treated with anti-CTLA-4 on Days 5, 8, and 11 post-inoculation. Tumor growth dynamics was depicted in the line graph (A, n = 4). Tumors were harvested to evaluate the infiltration of CD4⁺ and CD8⁺ T cells (B, n = 7 for untreated and 8 for treated groups of both WT and Gfi1^cKO mice) and IFN-γ production by CD8⁺ TILs (C, n = 7 for untreated WT mice, = 8 for treated WT mice, = 5 for untreated Gfi1^cKO mice, and = 6 for treated Gfi1^cKO mice). D WT (n = 4 in the untreated group and = 5 in the treated group) and Gfi1^cKO (n = 7 in the untreated group and 5 in the treated group) mice bearing palpable MC38 bladder tumors were treated with or without anti-CTLA-4 on Days 5, 8, and 11 post-tumor inoculation. Tumor growth dynamics was shown in the line graph. E, F Tumors were harvested to evaluate the infiltration of CD4⁺ and CD8⁺ T cells (E n = 8 for untreated WT and 9 for treated WT; n = 11 for untreated Gfi1^cKO and 12 for treated Gfi1^cKO) and IFN-γ production by CD8⁺ TILs (F n = 9 for untreated and treated WT; n = 11 for untreated Gfi1^cKO and 12 for treated Gfi1^cKO). Data (mean ± s.e.m.) were pooled results from 2-3 independent experiments, with each dot denoting a mouse. Two-way ANOVA with Holm-Sidak post hoc test was used. Source data are provided as a Source Data file.